Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

114.03
-1.2050-1.05%
Post-market: 114.950.9235+0.81%19:30 EDT
Volume:878.99K
Turnover:100.01M
Market Cap:12.33B
PE:251.35
High:115.98
Open:114.29
Low:111.94
Close:115.23
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.91
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.46
PE(LYR):139.05

Loading ...

Corcept Therapeutics Announces New Endocrinology Division President

TIPRANKS
·
Sep 23

Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires

Reuters
·
Sep 23

Corcept Announces Planned Leadership Transition

THOMSON REUTERS
·
Sep 23

Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72

Reuters
·
Sep 19

Corcept Therapeutics Price Target Maintained with a $165.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 19

Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)

TIPRANKS
·
Sep 19

Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer

Reuters
·
Sep 18

Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026

THOMSON REUTERS
·
Sep 18

Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

THOMSON REUTERS
·
Sep 18

Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares

Reuters
·
Sep 17

S&P 500 to Add Bloom Energy, Illumina and Everpure in September Rebalance

Tiger Newspress
·
Sep 05

Corcept Names Roberto Vieira as President, Oncology in Initial Beneficial Ownership Filing

Reuters
·
Sep 04

Corcept Therapeutics Insider Makes Major Multimillion-Dollar Stock Move

TIPRANKS
·
Aug 29

Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million

Reuters
·
Aug 28

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)

TIPRANKS
·
Aug 21

Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million

Reuters
·
Aug 21

Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million

Reuters
·
Aug 19

Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50

THOMSON REUTERS
·
Aug 18

Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating

MT Newswires Live
·
Aug 18

Corcept Therapeutics Earnings Call Signals Accelerating Growth

TIPRANKS
·
Aug 18